Tardive dyskinesia and other movement disorders secondary to aripiprazole.

摘要: The objective of this report is to draw attention tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. TD has been traditionally attributed typical (first-generation) antipsychotics, but other dopamine receptor blocking drugs and atypical (second- third-generation) neuroleptics are emerging as an important cause TD. We reviewed the medical records patients with seen at Baylor College Medicine Movement Disorders Clinic between 2002 2010 identify associated aripiprazole. Among 236 over specified period, 8 (3.4%) were found have aripiprazole-associated In 5 patients, occurred after exclusive exposure mean age onset was 55.8 ± 14.8 years female predominance. average duration treatment aripiprazole 18.4 26.4 months. Oro-bucco-lingual stereotypy in all patients. most did not spontaneously improve stopping Of treated tetrabenazine, 4 improved during follow-up. Although antipsychotic, promoted low risk TD, drug accounts for about 3.5% evaluated movement disorders clinic. This largest reported series draws growing incidence drug-induced "atypical antipsychotics."